Breakthrough combination therapy for depression approved

A breakthrough combination therapy to help treat depression has been approved by the FDA.

Aptar Pharma

Aptar Pharma - Bidose

Aptar Pharma’s Biodose nasal spray device has been designed to deliver accurate two-shot nasal medication for patients with depression.

The announcement marks the first FDA approval and US launch of a prescription drug using Aptar Pharma’s drug delivery system.

Aptar Pharma used its portfolio of stage-specific packages, designed to address regulatory needs, to help accelerate FDA approval.

“We are pleased that Aptar Pharma’s Bidose nasal delivery device has been approved by the FDA for this breakthrough therapy in the field of depression,” explained Gael Touya, president, Aptar Pharma. “This project marks close to a 10-year customer collaboration and once again demonstrates Aptar Pharma’s ability to develop and launch complex drug delivery systems worldwide.”